Literature DB >> 26187166

Stability of micafungin sodium solutions at different concentrations in glass bottles and syringes.

Thomas Briot1, Sandy Vrignaud2, Frédéric Lagarce3.   

Abstract

Micafungin is a costly treatment and packaging of 50 mg or 100 mg bottles only are available, while doses lower than 5 mg and 20 mg are often necessary in neonates and paediatrics patients, respectively. The stability of micafungin sodium in polypropylene syringes and glass bottles was studied at different concentrations. Solutions of micafungin diluted with NaCl 0.9% were prepared in glass bottles (20 and 10 mg/mL) or syringes (1 and 0.5 mg/mL) and stored at 25 °C, 60% humidity (RH), in the dark (ICH conditions). Solutions were also exposed to heat (70 °C) or alkaline solution (NaOH) in order to force degradation. Samples were analysed at days 1, 5, 8 (for bottles) and also 15 (for syringes) after the preparation and assayed in triplicate. Stability was studied using a stability-indicating high-performance liquid chromatographic method. Syringes stored at 25 °C retained over 90% of their initial concentration over the study period. Temperature and alkaline conditions had significant effect on the stability of micafungin, leading to apparition of degradation products. Moreover, sub visible particles were in the specification of the European Pharmacopeia along 15 days. To conclude, micafungin diluted in NaCl 0.9% and stored in polypropylene syringes was chemically stable for at least 15 days at 25 °C in the dark.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CIVAS; HPLC; Micafungin; Polypropylene syringe; Stability

Mesh:

Substances:

Year:  2015        PMID: 26187166     DOI: 10.1016/j.ijpharm.2015.07.019

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  1 in total

1.  Physical Compatibility of Micafungin With Sodium Bicarbonate Hydration Fluids Commonly Used With High-Dose Methotrexate Chemotherapy.

Authors:  Logan C Joiner; Clay Tynes; John Arnold; Rachel R Miller; Greg Gorman
Journal:  Hosp Pharm       Date:  2017-11-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.